Video

Ushering in the Golden Era of Alzheimer Drug Development?

Author(s):

RJ Tesi, MD

What effect will aducanumab have on Alzheimer disease treatment?

RJ Tesi, MD, discusses the recent aducanumab FDA approval and the implications it will have on the treatment of Alzheimer disease.

Dr Tesi is CEO and Chief Medical Officer of INmuneBio.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
Related Content
dementia
October 23rd 2024

Evaluating Brexpiprazole for the Management of Behavioral and Psychological Symptoms of Dementia

Anil K. Bachu, MD Rashmi Phadke Subhedar, MD Maliha I. Ansari, MD Senthil Rajaram Manoharan, MD Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP
What Will the Future of Alzheimer Disease Treatment Look Like?
July 23rd 2021

What Will the Future of Alzheimer Disease Treatment Look Like?

Helen Lavretsky, MD, MS
aging brain
October 1st 2024

Traumatic Brain Injury’s Impact on Normal Aging and Neurodegenerative Diseases

Grace S. Griesbach, PhD
Site Logo
August 16th 2012

The Relevance of New Alzheimer Guidelines for Clinical Practice

Christopher Van Dyck, MD
dementia
July 18th 2024

Treatment Options for the Management of Behavioral and Psychological Symptoms of Dementia

Anil K. Bachu, MD Rashmi Phadke Subhedar, MD Maliha I. Ansari, MD Senthil Rajaram Manoharan, MD Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP
FDA approval
July 2nd 2024

Alzheimer Disease Treatment Donanemab Receives FDA Approval

Leah Kuntz
© 2024 MJH Life Sciences

All rights reserved.